Please assess the completion status of the following clinical trial:

Trial Title: A Study of Tocilizumab (RoActemra/Actemra) in Patients With Ankylosing Spondylitis Who Have Had an Inadequate Response to Previous Tumor Necrosis Factor (TNF) Antagonist Therapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Adult patients ≥ 18 years of age.~* Ankylosing spondylitis as defined by the modified New York criteria for ≥ 3 months prior to baseline.~* Active disease at screening and baseline (Bath Ankylosing Spondylitis Disease Activity Index \[BASDAI\] ≥ 4.0, spinal pain visual analog scale \[VAS\] ≥ 40).~* Inadequate response or intolerant to 1 or more previous non-steroidal anti-inflammatory drugs (NSAIDs).~* Inadequate response to treatment with etanercept, infliximab, adalimumab, or golimumab because of inadequate efficacy.~* Tumor necrosis factor (TNF) antagonist therapy must have been discontinued at least 8 weeks prior to baseline (etanercept 4 weeks).~* Traditional disease-modifying anti-rheumatic drugs (DMARDs) must be withdrawn for at least 4 weeks prior to baseline (methotrexate, sulfasalazine, and hydroxychloroquine or chloroquine may be allowed if at stable dose for at least 4 weeks prior to baseline).~* Oral corticosteroids (≥ 10 mg/day prednisone or equivalent) and NSAIDs/cyclooxygenase-2 \[COX-2\] inhibitors must be at stable dose for at least 4 weeks prior to baseline.~Exclusion Criteria:~* Major surgery (including joint surgery) within 8 weeks prior to screening or planned major surgery within 6 months after randomization.~* Total ankylosis of spine (as determined by investigator).~* Inflammatory rheumatic disease other than ankylosing spondylitis.~* Active, acute uveitis at baseline.~* Previous treatment with tocilizumab.~* Intra-articular or tendon injections or parenteral corticosteroids within 4 weeks prior to screening.~* History of severe allergic or anaphylactic reactions to humanized or murine monoclonal antibodies.~* Active current or history of recurrent bacterial, viral, fungal, mycobacterial, or other infection.~* History of or currently active primary or secondary immunodeficiency.~* Body weight \> 150 kg.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Tocilizumab 4 mg/kg (Type: EXPERIMENTAL): Patients received tocilizumab 4 mg/kg intravenously every 4 weeks for 24 weeks.
- Tocilizumab 8 mg/kg (Type: EXPERIMENTAL): Patients received tocilizumab 8 mg/kg intravenously every 4 weeks for 24 weeks.
- Placebo (Type: PLACEBO_COMPARATOR): Patients received placebo to tocilizumab intravenously every 4 weeks for 24 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).